Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
Date:11/11/2009

HAIKOU CITY, China, Nov. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE/AMEX: CPHI), which manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the third quarter ended September 30, 2009.

    Third Quarter 2009 Financial Highlights

    -- Revenue increased 23.1% to $15.5 million from $12.6 million in the
       third quarter of 2008;

    -- Net Income, including adjustment in Bad Debt Estimates, was $7.2
       million, compared to $4.3 million in the third quarter of 2008;

    -- Year-to-Date Net Cash from Operations increased by 59% to $6.4 million
       compared to $4.0 million for the same period of 2008; and

    -- EPS was $0.17, compared to $0.10 in the third quarter of 2008.

For the three months ended September 30, 2009, we saw an increase of 23% in revenue to $15.5 million compared to the same period of last year. This is an increase of $2.9 million from the $12.6 million we generated in the corresponding period of 2008. Notably, third quarter sales in the Anti-Viro/Infection & Respiratory product category rose by 36% over the same period a year ago to approximately $6.1 million. Our CNS and Cerebral & Cardio Vascular drugs performed steadily by generating $5.6 million revenue during the third quarter, compared to $5.9 million in the same period of 2008. Our Other Products category (including our tumor drug Granisetron and various other products) saw an increase of 36% over last year to $2.3 million. Our Digestive product sales rose by 184% to $1.5 million, mainly due to the sales contribution from our new product Tiopronin. During this quarter we saw Tiopronin generating close to $800,000 in sales. This is progressing better than expected.

Gross Profit for the three months ended Septem
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results
2. China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results
3. Monsanto Opens First Biotechnology Research Center in China
4. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
5. China-Biotics, Inc. Appoints New Vice President
6. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
7. China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. China Medical Technologies Announces the SFDA Approval for its SPR System
10. China Integrated Energy, Inc. Announces Preliminary Third Quarter Financial Results and Increases Full Year Guidance
11. China Integrated Energy, Inc. Announces Eight Million Share Public Follow-On Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... DUBLIN, Ireland, January 9 Azur Pharma ... the exclusive U.S. marketing rights,for Niravam(R) (alprazolam ... Kemstro(TM) (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine ... terms were not,disclosed. , ...
... The IN VIVO Blog , which provides news, insights and ... a Deal of the Year for 2008 -- ... than 2,500 reader votes were cast in this inaugural competition, ... the 13 nominees selected by The IN VIVO Blog,s writers ...
... MATK ) announced today that it will be ... The conference is being held January 14-15, 2009 at ... Point, California. Peter L. Buzy, Chief Financial Officer, and ... 2009 at 1:25 PM PT.A live audio webcast of Martek,s ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Wash. -- A new study reveals how pollution causes ... Appearing in the Proceedings of the National Academy ... long-standing debate and reveal how pollution plays into climate ... the accuracy of weather and climate models. Researchers ...
... that protect it from insect damage has been grown in the ... are derived from a bacterium called Bacillus thuringiensis , these ... has been highly effective against the European corn borer, it has ... documented to show resistance to the Bt proteins. In a new ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
Cached Biology News:The lingering clouds 2The lingering clouds 3Scientists offer recommendations for delaying resistance to Bt corn in western corn rootworm 2